Best Practice & Research Clinical Haematology最新文献_第8页

Allogeneic hematopoietic cell transplantation in acute myeloid leukemia 异基因造血细胞移植治疗急性髓性白血病

IF 2.1 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2023-06-01 DOI: 10.1016/j.beha.2023.101466

Gray Magee, Brittany Knick Ragon

引用次数: 0

Dermatologic complications in transplantation and cellular therapy for acute leukemia 急性白血病移植和细胞治疗中的皮肤并发症

IF 2.1 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2023-06-01 DOI: 10.1016/j.beha.2023.101464

Shahab Babakoohi , Stephanie L. Gu , Hamid Ehsan , Alina Markova

引用次数: 0

What is relative survival and what is its role in haematology? 什么是相对生存?它在血液学中的作用是什么?

IF 2.1 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2023-06-01 DOI: 10.1016/j.beha.2023.101474

Maja Pohar Perme , Liesbeth C. de Wreede , Damjan Manevski

{"title":"What is relative survival and what is its role in haematology?","authors":"Maja Pohar Perme , Liesbeth C. de Wreede , Damjan Manevski","doi":"10.1016/j.beha.2023.101474","DOIUrl":"10.1016/j.beha.2023.101474","url":null,"abstract":"<div><p>In many haematological diseases, the survival probability is the key outcome. However, when the population of patients is rather old and the follow-up long, a significant proportion of deaths cannot be attributed to the studied disease. This lessens the importance of common survival analysis measures like overall survival and shows the need for other outcome measures requiring more complex methodology. When disease-specific information is of interest but the cause of death is not available in the data, relative survival methodology becomes crucial. The idea of relative survival is to merge the observed data set with the mortality data in the general population and thus allow for an indirect estimation of the burden of the disease.</p><p>In this work, an overview of different measures that can be of interest in the field of haematology is given. We introduce the crude mortality that reports the probability of dying due to the disease of interest; the net survival that focuses on excess hazard alone and presents the key measure in comparing the disease burden of patients from populations with different general population mortality; and the relative survival ratio which gives a simple comparison of the patients' and the general population survival. We explain the properties of each measure, and some brief notes are given on estimation. Furthermore, we describe how association with covariates can be studied. All the methods and their estimators are illustrated on a sub-cohort of older patients who received a first allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes or secondary acute myeloid leukemia, to show how different methods can provide different insights into the data.</p></div>","PeriodicalId":8744,"journal":{"name":"Best Practice & Research Clinical Haematology","volume":"36 2","pages":"Article 101474"},"PeriodicalIF":2.1,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9676582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacogenomics in allogeneic hematopoietic stem cell transplantation: Implications on supportive therapies and conditioning regimens 同种异体造血干细胞移植的药物基因组学:对支持疗法和调理方案的影响

IF 2.1 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2023-06-01 DOI: 10.1016/j.beha.2023.101470

Sarah A. Morris, D. Grace Nguyen, Jai N. Patel

引用次数: 0

Worldwide sources of data in haematology: Importance of clinician-biostatistician collaboration 血液学的全球数据来源:临床医生与生物统计学家合作的重要性

IF 2.1 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2023-06-01 DOI: 10.1016/j.beha.2023.101450

Kristin M. Page , Stephen R. Spellman , Brent R. Logan

引用次数: 0

Cellular and humoral immunotherapy in children, adolescents and young adults with non-Hodgkin lymphoma 非霍奇金淋巴瘤儿童、青少年和年轻人的细胞和体液免疫治疗

IF 2.1 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2023-03-01 DOI: 10.1016/j.beha.2023.101442

Yaya Chu , Aliza Gardenswartz , Caroline Diorio , Lianna J. Marks , Eric Lowe , David T. Teachey , Mitchell S. Cairo

{"title":"Cellular and humoral immunotherapy in children, adolescents and young adults with non-Hodgkin lymphoma","authors":"Yaya Chu , Aliza Gardenswartz , Caroline Diorio , Lianna J. Marks , Eric Lowe , David T. Teachey , Mitchell S. Cairo","doi":"10.1016/j.beha.2023.101442","DOIUrl":"10.1016/j.beha.2023.101442","url":null,"abstract":"<div><p>The prognosis is dismal (2-year overall survival less than 25%) for childhood, adolescent, and young adult (CAYA) with relapsed and/or refractory (R/R) non-Hodgkin lymphoma (NHL). Novel targeted therapies are desperately needed for this poor-risk population. CD19, CD20, CD22, CD79a, CD38, CD30, LMP1 and LMP2 are attractive targets for immunotherapy in CAYA patients with R/R NHL. Novel anti-CD20 monoclonal antibodies, anti-CD38 monoclonal antibody, antibody drug conjugates and T and natural killer (NK)-cell bispecific and trispecific engagers are being investigated in the R/R setting and are changing the landscape of NHL therapy. A variety of cellular immunotherapies such as viral activated cytotoxic T-lymphocyte, chimeric antigen receptor (CAR) T-cells, NK and CAR NK-cells have been investigated and provide alternative options for CAYA patients with R/R NHL. Here, we provide an update and clinical practice guidance of utilizing these cellular and humoral immunotherapies in CAYA patients with R/R NHL.</p></div>","PeriodicalId":8744,"journal":{"name":"Best Practice & Research Clinical Haematology","volume":"36 1","pages":"Article 101442"},"PeriodicalIF":2.1,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9182470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Editorial Board / Aims & Scope 编辑委员会/目标与范围

IF 2.1 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2023-03-01 DOI: 10.1016/S1521-6926(23)00016-6

引用次数: 0

Late effects and frontline treatment selection for children with non-Hodgkin lymphoma 儿童非霍奇金淋巴瘤的晚期效应和一线治疗选择

IF 2.1 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2023-03-01 DOI: 10.1016/j.beha.2023.101443

Matthew J. Ehrhardt , Stephanie B. Dixon , Jennifer Belsky , Jessica Hochberg

{"title":"Late effects and frontline treatment selection for children with non-Hodgkin lymphoma","authors":"Matthew J. Ehrhardt , Stephanie B. Dixon , Jennifer Belsky , Jessica Hochberg","doi":"10.1016/j.beha.2023.101443","DOIUrl":"10.1016/j.beha.2023.101443","url":null,"abstract":"<div><p>Approximately 1 in 640 adults between 20 and 40 years of age is a survivor of childhood cancer. However, survival has often come at the expense of increased risk of long-term complications, including chronic health conditions and higher mortality rates. Similarly, long-term survivors of childhood non-Hodgkin lymphoma (NHL) experience significant morbidity and mortality related to prior cancer treatments, highlighting the importance of primary and secondary prevention strategies to mitigate late toxicity. As a result, effective treatment regimens for pediatric NHL have evolved to reduce both short- and long-term toxicity through cumulative dose reductions and elimination of radiation. The establishment of effective regimens facilitates shared decision-making opportunities for frontline treatment selection that considers efficacy, acute toxicity, convenience, and late effects of treatments. The current review seeks to merge current frontline treatment regimens with survivorship guidelines to enhance understanding of potential long-term health risks to facilitate best treatment practices.</p></div>","PeriodicalId":8744,"journal":{"name":"Best Practice & Research Clinical Haematology","volume":"36 1","pages":"Article 101443"},"PeriodicalIF":2.1,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9407967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Diagnosis and management of Hodgkin lymphoma in children, adolescents, and young adults 儿童、青少年和年轻人霍奇金淋巴瘤的诊断和治疗

IF 2.1 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2023-03-01 DOI: 10.1016/j.beha.2023.101445

Jennifer A. Belsky , Jessica Hochberg , Lisa Giulino-Roth

引用次数: 3

Diagnosis and management of ALK-positive anaplastic large cell lymphoma in children and adolescents 儿童和青少年alk阳性间变性大细胞淋巴瘤的诊断和治疗

IF 2.1 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2023-03-01 DOI: 10.1016/j.beha.2023.101444

Charlotte Rigaud , Fabian Knörr , Laurence Brugières , Wilhelm Woessmann

{"title":"Diagnosis and management of ALK-positive anaplastic large cell lymphoma in children and adolescents","authors":"Charlotte Rigaud , Fabian Knörr , Laurence Brugières , Wilhelm Woessmann","doi":"10.1016/j.beha.2023.101444","DOIUrl":"10.1016/j.beha.2023.101444","url":null,"abstract":"<div><p>Anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) is a CD30-positive T cell lymphoma characterized by signalling from constitutively activated ALK fusion proteins. Most children and adolescents present in advanced stages, often with extranodal disease and B symptoms. The current front-line therapy standard of six cycles polychemotherapy reaches an event-free survival of 70%. The strongest independent prognostic factors are minimal disseminated disease and early minimal residual disease. At relapse, ALK-inhibitors, Brentuximab Vedotin, Vinblastine, or second line chemotherapy are effective re-inductions. Survival at relapse exceeds 60–70% with consolidation according to the time of relapse (Vinblastine monotherapy or allogeneic hematopoietic stem cell transplantation) so that the overall survival reaches 95%. It needs to be shown whether check-point inhibitors or long-term ALK-inhibition may substitute for transplantation. The future necessitates international cooperative trials testing whether a shift of paradigm to a chemotherapy-free regimen can cure ALK-positive ALCL.</p></div>","PeriodicalId":8744,"journal":{"name":"Best Practice & Research Clinical Haematology","volume":"36 1","pages":"Article 101444"},"PeriodicalIF":2.1,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9175047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4